Overcoming challenges and embracing innovation in biopharmaceutical manufacturing
The article is based on a podcast and interview with Janet Hoogstraate in March 2025. The biopharmaceutical industry is evolving rapidly, and innovation in manufacturing is playing a crucial role ...
X marks the spot
Discover a rich history of GMP manufacture, CMC experience and regulatory expertise. NorthX Biologics offers a comprehensive spectrum of biologics, including recombinant proteins, virus products, extracellular vesicles, and an array ...
Podcast with investor Ted Fjällman
NorthX Biologics’ investor and CEO of Flerie, Ted Fjällman made a guest appearance in a recent episode of Värdeskaparna, a podcast taking the audience behind the scenes in the private ...
Q podden with CEO Janet Hoogstraate
Janet Hoogstraate, the CEO of NorthX Biologics, recently appeared in an episode of Q-podden, a podcast on manufacturing, quality and corporate culture in life science. Janet discusses the latest trends and ...
Ensuring every child is vaccinated
On behalf of the Swedish Ministry for Foreign Affairs and Gavi, the Global Vaccine Alliance, NorthX Biologics’ CEO Janet Hoogstraate participated in an important roundtable on “Leveraging Technology and Innovation to Ensure Every ...
The rise of the CDMO era – an investor’s perspective
Based on a presentation given by Thomas Eldered at the PharmaOutsourcing event, Stockholm, Sweden, December 2024. From vertical integration to decentralization The pharmaceutical industry has undergone a seismic shift over ...
Q podden with CQO Thomas Beck
Thomas Beck, the Chief Quality Officer (CQO) at NorthX Biologics, was recently featured in an episode of Q podden, a podcast on manufacturing, quality and corporate culture in life science. In ...
Navigating Novo Nordisk’s acquisition of Catalent
In this episode of the Molecule to Market podcast, NorthX Biologics CEO Janet Hoogstraate was invited to discuss the implications of integrating Catalent’s capabilities into Novo Nordisk’s operations and what ...
Navigating the regulatory and manufacturing realities of mRNA therapeutic development
The increasingly dynamic and multifaceted landscape of mRNA therapeutics is posing new regulatory and manufacturing challenges. Both startups and established biopharma companies require innovative solutions to help them meet the ...